FIXX - Homology Medicines GAAP EPS of $1.59 beats by $1.52

Homology Medicines press release (NASDAQ:FIXX): Q1 GAAP EPS of $1.59 beats by $1.52. Collaboration revenues for the quarter ended March 31, 2022 were $0.8 million, compared to $29.3 million for the quarter ended March 31, 2021. Collaboration revenues for the three months ended March 31, 2021 included the recognition of approximately $28.5 million of deferred revenue and reimbursement of R&D expenses as a result of concluding the Company’s collaboration with Novartis. As of March 31, 2022, Homology had approximately $256.1 million in cash, cash equivalents and short-term investments

For further details see:

Homology Medicines GAAP EPS of $1.59 beats by $1.52